Loading
A phase 1/2 trial of Fludarabine in renal cell carcinoma, run by Beijing Biotech, now recruiting.
Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma is a phase 1/2 interventional study registered as NCT07551349 by Beijing Biotech, with 36 participants planned, started 2026-02-02 and due to reach its primary completion in 2027-04-14. Interventions recorded: EB-701/CA9-NK, Fludarabine. Conditions listed: Advanced or Metastatic Clear Cell Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Clear cell renal cell carcinoma, Fludarabine, Renal cell carcinoma.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma.
Shares Fludarabine, Cytotoxic chemotherapy.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/